Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab plus chemotherapy followed by cryoablation in extensive-stage small cell lung cancer
ChiCTR2600135156Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of serplulimab in small cell lung cancer (SCLC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 1-year progression-free survival rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600135156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135156.